ClinicalTrials.gg
Status unknownNCT05501158Updated Aug 19, 2022

CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population

An interventional study of Tamoxifen in Breast Cancer, sponsored by Nalagenetics Pte Ltd. Status unknown at 1 site in Indonesia. Open to female participants. Per ClinicalTrials.gov, last updated 2022-08-19.

Sponsored by Nalagenetics Pte Ltd · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2021, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 133 studies testing tamoxifen in Breast Neoplasms — 16 open to participants now, 30 under way, 9 of them phase 3. Tamoxifen · Breast Neoplasms.

Enrollment
65th of 126
150 · median 169
Started
2021
with 4 others
No phase
9 of 133
1 open now
Registered
120th of 133
by date

Among the 133 studies testing tamoxifen in Breast Neoplasms, this one is the 65th largest by enrollment of the 126 interventional ones that give a count, is one of 5 that started in 2021, is one of 9 with no phase, and was the 120th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 133 studies testing tamoxifen in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About tamoxifen

Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies testing tamoxifen in Breast Neoplasms, or all of them as a file.
02

Study summary

The utilization of tamoxifen is considerably high in Indonesia, with about 170,000 tamoxifen prescriptions filed in 2015. It is metabolized by the enzyme CYP2D6, resulting in its active metabolite, endoxifen, which has been proven to be effective in the prevention and treatment of breast cancer.

Studies showed the CYP2D6 gene has more than 100 variants; some of which are linked with reduced drug activity, while others do not have any pathological implications. The metabolizer profile of these variants is generally grouped into Ultra-rapid, Normal, Intermediate, and Poor Metabolizers (UM, NM, IM, and PM, respectively). In our previous study (NCT04312347), the investigators recruited 150 breast cancer patients who were taking adjusted dose of tamoxifen daily based on their CYP2D6 phenotype. Although the investigators have measured the endoxifen level of the patients with adjusted treatment, the clinical outcomes of the study are not yet conclusive.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. female
  2. diagnosed with ER+ breast cancer
  3. have been genotyped and classified as PM and IM in the previous study
  4. are recommended by doctor to take tamoxifen 40 mg according to their metabolizer profile
  5. have finished the definitive therapy course (surgery, chemotherapy, or radiotherapy).

Exclusion criteria

Exclusion Criteria:

  1. have other primary cancer aside from breast cancer.
  2. those with residual tumor cells/have experienced second primary breast tumor.
  3. patients who are recommended by doctor to switch to aromatase inhibitors (AI)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Dose adjustment of tamoxifen

    Following the CPIC guidelines, those identified as Poor Metabolizers (PMs) and Intermediate Metabolizers (IMs) from our previous study are recommended to adjust their tamoxifen dosage to 40 mg per day.

    Drug: Tamoxifen

  • No intervention
    Standard dose of tamoxifen

    Those identified as Normal Metabolizers (NMs) from our previous study remain on tamoxifen 20 mg per day.

Interventions

  • Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations

06

What researchers measure

Primary outcomes

  1. Overall Survival rate

    The percentage of study participants who are still alive by the end of this study after being diagnosed with breast cancer

    Time frame: 3 year

  2. Progression Survival rate

    The percentage of study participants who live with the disease but the disease does not get worse by the end of this study

    Time frame: 3 year

Other outcomes

  1. Long-term side effects of tamoxifen

    Long-term side effects of tamoxifen, including heartburn, thromboembolic event, endometrial hyperplasia and uterine cancer, will also be monitored and documented using the Adverse Drug Reaction (ADR) reporting form provided by the Indonesian National Agency of Drug and Food Control.

    Time frame: 3 year

07

Study locations

1 site
  • MRCCC Siloam Hospitals Semanggi
    Jakarta, DKI Jakarta 12930, Indonesia
08

References and documents

Publications

  • Braal CL, Jager A, Hoop EO, Westenberg JD, Lommen KMWT, de Bruijn P, Vastbinder MB, van Rossum-Schornagel QC, Thijs-Visser MF, van Alphen RJ, Struik LEM, Zuetenhorst HJM, Mathijssen RHJ, Koolen SLW. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clin Pharmacokinet. 2022 Apr;61(4):527-537. doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17. PubMed 34786650 ↗
  • Sanchez-Spitman A, Dezentje V, Swen J, Moes DJAR, Bohringer S, Batman E, van Druten E, Smorenburg C, van Bochove A, Zeillemaker A, Jongen L, Los M, Neven P, Gelderblom H, Guchelaar HJ. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. J Clin Oncol. 2019 Mar 10;37(8):636-646. doi: 10.1200/JCO.18.00307. Epub 2019 Jan 24. PubMed 30676859 ↗
  • Lu J, Li H, Guo P, Shen R, Luo Y, Ge Q, Shi W, Li Y, Zhu W. The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis. Onco Targets Ther. 2017 Nov 13;10:5429-5437. doi: 10.2147/OTT.S149197. eCollection 2017. PubMed 29180876 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Apr 2024, 39 months after the start.

Of 110 industry-sponsored interventional studies with no phase under Breast Neoplasms, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 59. This study's planned 39 months is above that.

Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2022
First posted
Aug 15, 2022
StartActual
Jan 1, 2021
Primary completionEst.
Apr 30, 2024
CompletionEst.
Jun 30, 2024
Last update
Aug 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05501158
Lead sponsor
Nalagenetics Pte Ltd
Collaborators
SJH Initiatives, Indonesia University, MRCCC Siloam Hospitals Semanggi
Responsible party
Sponsor
First posted
Aug 15, 2022
Start date
Jan 1, 2021
Primary completion
Apr 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Aug 19, 2022

Study contacts

Baitha Maggadani, MPharm
study chair · Fakultas Farmasi Universitas Indonesia
Arief Winata, MD
study chair · MRCCC Siloam Hospitals Semanggi
Samuel Haryono, MD, PhD
principal investigator · SJH Innitiatives
Fatma Aldila, PharmD
study chair · Nalagenetics Pte Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion